|
39 documents found matching cs:senate*.
|
|
of 4
Prev
Next
|
|
|
|
Showing 1-10 of 39 documents
|
1.
[Letter from Charles Nemeroff to Thomas Lawley regarding consulting activities]
|
Document Date:
|
20000522
|
|
Author:
|
Nemeroff, Charles
|
|
Recipient:
|
Lawley, Thomas
|
|
Corporate Recipient:
|
Emory School of Medicine
|
|
Document Type:
|
letter
|
|
Named Organization:
|
American Foundation for Suicide Prevention|National Depression and Manic-Depression Disorders Association|Anxiety Disorders Association of America|American Psychiatric Association Research Institute|Solvay Pharmaceutical Advisory Board|Smith-Kline Beecham|Eli Lilly|Janssen|Pharmacia-Upjohn|AstraZeneca|Merck|Bristol-Myers-Squibb|Wyeth-Ayerst|Pfizer|Forrest Lab|Organon|George West Mental Health Foundation|Corcept|Neurocrine Biosciences|NIMH|NASA|Max Planck Institute|NIH
|
|
Case Number:
|
US Senate Finance Committee
|
|
Bates Number:
|
SENFIN0003-0004
|
|
Search Terms in Context:
|
EMORY UNIVERSITY SCHOOL OF MEDICINE
DEPARTMENT OF PSYCHIATRY AND BEHAVIORAL SCIENCES 1639 Pierce Drive, Suite 4000 Atlanta, Georgia 30322
WMB Bldg,
Charles B. Nemeroff, MD, PhD I———
Reunetle W. Harris Professor and Chairman FAX DMtMiHNP
e- mall: <—»3©emory.eclu
May 22, 2000
Confidential c^«-,. y¿"
|
|
Bookmark:
|
http://dida.library.ucsf.edu/tid/oxx09b10
|
|
| |
2.
RE: Nemeroff
|
Document Date:
|
20060829
|
|
Author:
|
Seiton, Brenda
|
|
Recipient:
|
Adkison, Claudia
|
|
Document Type:
|
e-mail|memo
|
|
Named Person:
|
Johns, Mike|Lawley, Tom
|
|
Named Organization:
|
Emory University
|
|
Case Number:
|
US Senate Finance Committee
|
|
Bates Number:
|
SENFIN0101-0102
|
|
Search Terms in Context:
|
From: Seiton, Brenda J
Sent: Tuesday, August 29,2006 11:42 AM
To: Adkison, Claudia R
Subject: RE: nemeroff
Importance: High
Claudia,
Ifs on your chair. I have not gone through the grants to which drugs are involved with the grant. As you can see, he has very few pharma sponsored studies. Jeff and I will have to look through each grant to see which drugs are involved in the study and determine whether there is a potential conflict. He does seem to try to keep his consulting fees to less than $10k for companies that are producing drugs that he studies. In looking at the IRB protocols, he did not disclose that he had a relationship with the makers of the drugs; however, the question on the IRB forms asked whether anyone has a relationship with the sponsor, the technology, or if the drug/technology was developed at Emory- he answered the questions correctly.
|
|
Bookmark:
|
http://dida.library.ucsf.edu/tid/oxx09w10
|
|
| |
3.
Nemeroff - Cypress Biosciences
|
Document Date:
|
20040326
|
|
Corporate Author:
|
Emory University
|
|
Recipient:
|
Seiton, Brenda
|
|
Corporate Recipient:
|
Emory University
|
|
Document Type:
|
e-mail|memo
|
|
Named Person:
|
Nemeroff
|
|
Case Number:
|
US Senate Finance Committee
|
|
Bates Number:
|
SENFIN0019
|
|
Search Terms in Context:
|
Brenda Seiton
From:
Sent:
To:
Cc:
Subject:
HJBBBE@emory.edu] Friday, March 26, 2004 9:28 AM
Nemeroff - Cypress Biosciences
Dear Brenda,
Dr. Nemeroff asked me to let you know that, effective March 25, 2004, he has resigned from the Board of Directors of Cypress Biosciences. He will remain as a consultant to the company for a period of two years (@ $50,000 per year). He will retain the stock he has, but will receive no additional shares.
If you have any questions, please let us know.
Thanks
1
pgNbr=1
|
|
Bookmark:
|
http://dida.library.ucsf.edu/tid/oxx09h10
|
|
| |
4.
RE: Nemeroff Solvay Consulting Agreement
|
Document Date:
|
20070920
|
|
Author:
|
Johns, Michael ME
|
|
Corporate Author:
|
Emory University
|
|
Recipient:
|
Adkison, Claudia
|
|
Corporate Recipient:
|
Emory University
|
|
Document Type:
|
e-mail|memo
|
|
Named Person:
|
Lawley, Thomas|Seiton, Brenda
|
|
Named Organization:
|
Solvay
|
|
Case Number:
|
US Senate Finance Committee
|
|
Bates Number:
|
SENFIN0113
|
|
Search Terms in Context:
|
From: Johns, Michael M E
Sent: Thursday, September 20,2007 3:04 PM
To: 'flJBBËBHBV; Adkison, Claudia R
Subject: RE: Nemeroff Solvay Consulting Agreement
I also note the contract is calling for no more than 85 hours at 400dollars per hour. That is 10-1/2 days of consulting. If his other five agreements are similar he is exceeding his one day a week limit.
Michael M.E. Johns MD
CEO Woodruff Health Sciences Center
EVP Health Affairs
1440 Clifton Rd. NE
Suite 400
Atlanta, &A 30322
PhmÊÊÊÊÊÊmtm-Fx «¦¦¦¦*
From: 4HBBBHBBHft[mailtdMHB|V§)emory.edu] Sent: Thursday, September 20, 2007 2:45 PM To: Johns, Michael M E; Adkison, Claudia R Subject: FW: Nemeroff Solvay Consulting Agreement
FROM DEAN THOMAS J. LAWLEY. M.P.
Thoughts? Tom
From: Charles B. Nemeroff [mailtoiBBB0@emory.edu]
Sent: Tuesday, September 18, 2007 7:57 AM
To: Tom Lawley
Subject: Fwd: Nemeroff Solvay Consulting
|
|
Bookmark:
|
http://dida.library.ucsf.edu/tid/oxx10e10
|
|
| |
5.
RE: Educational Grant for Grand Rounds
|
Document Date:
|
20070104
|
|
Author:
|
Nemeroff, Charles
|
|
Corporate Author:
|
Emory University
|
|
Document Type:
|
e-mail|memo
|
|
Named Organization:
|
Otsuka|ACNP
|
|
Case Number:
|
US Senate Finance Committee
|
|
Bates Number:
|
SENFIN0112
|
|
Search Terms in Context:
|
ßrenda Seiton
Page 1 of 1
From: Charles B Nemeroff [flHBH@emory.edu] Sent: Thursday, January 04, 2007 11:08 AM
Ce: tiHrtjMaapedu; Michael Johns; Brenda Seiton J.D. Assistant Dean for Administration Subject: Re: Educational Grant for Grand Rounds
DearflH^,
Thanks so much for your unrestricted educational grant to support Grand Rounds in our Department. Also thanks for your kind words about
my consulting to Otsuka in the past. My decision is firm to markedly limit my consulting and service on Scientific Advisory Boards with pharmaceutical
companies. I wish you and your colleagues at Otsuka success in your future endeavors. I would be pleased to discuss taking part in accredited CME activities on occasion. Charlie
At 09:40 AM 1/4/2007, you wrote:
Hi Charlie: ____
Wishing you andflHfc wonderful new year!
I wanted to pass a note your way to let you know that Otsuka contributed $5500 to Emory Department of Psychiatry Grand Rounds. It looks like you have a great line up, and I hope
|
|
Person Copied:
|
Johns, Michael|Seiton, Brenda
|
|
Bookmark:
|
http://dida.library.ucsf.edu/tid/oxx10d10
|
|
| |
6.
Review of Dr. Nemeroff's Grants and Outside Activities
|
Document Date:
|
20040526
|
|
Corporate Author:
|
School of Medicine Conflict of Interest Committee
|
|
Recipient:
|
Lawley, Thomas
|
|
Corporate Recipient:
|
Emory University
|
|
Document Type:
|
memo
|
|
Named Person:
|
Nemeroff|Seiton|Musselman
|
|
Named Organization:
|
Acadia Pharmaceuticals|Bristol Myers Squibb|Corcept Therapeutics|Cyberonics|Cypress Bioscience|Janssen|Lilly Research Laboratories|Merck|Otsuka|Somerset|SCIREx|Abbott|AstraZeneca|Comprehensive Neuroscience|George West Mental Health Foundation|GlaxoSmithKline|Neurocrine Biosciences|Wyeth-Ayerst|NIMH|Johnson & Johnson
|
|
Case Number:
|
US Senate Finance Committee
|
|
Bates Number:
|
SENFIN0020-0033
|
|
Search Terms in Context:
|
í
Ti
EMORY
UNIVERSITY SCHOOL OF
MEDICINE
Office of the Dean
MEMORANDUM
TO: Thomas J. Lawley, M.D., Dean
FROM: School of Medicine Conflict of Interest Committee
DATE: May 26, 2004
RE: Review of Dr. Nemeroff s Grants and Outside Activities
CC: Claudia R. Adkison, J.D., Ph.D., Executive Associate Dean/Faculty
Affairs & Administration
Overview
At your request, the Committee1 reviewed Dr. Nemeroff s outside activities and his grants sponsored by companies with whom he has consulting relationships during its monthly meetings of October, November, and December 2003. The Committee reviewed his written, compensated, consulting agreements from Acadia Pharmaceuticals, Bristol Myers Squibb, Corcept Therapeutics, Cyberonics, Cypress Bioscience, Janssen Pharmaceutical Products, Lilly Research Laboratories, Merck, Otsuka, Somerset, and SCIREx. Of all of these agreements, only the SCIREX agreement had ever been provided to the Dean's Office for the req
|
|
Person Copied:
|
Adkison, Claudia
|
|
Bookmark:
|
http://dida.library.ucsf.edu/tid/oxx09i10
|
|
| |
7.
Meeting
|
Document Date:
|
20060814
|
|
Author:
|
Nemeroff, Charles
|
|
Corporate Author:
|
Emory University
|
|
Recipient:
|
Johns, Michael|Lawley, Tom
|
|
Document Type:
|
e-mail|memo
|
|
Case Number:
|
US Senate Finance Committee
|
|
Bates Number:
|
SENFIN0100
|
|
Search Terms in Context:
|
ÖU
From: Sent: To: Subject:
Charles B. Nemeroff [«¦¦¦V@emory.edu] Monday, August 14, 2006 8:23 PM Michael Johns; Tom Lawley meeting
Dear Mike and Tom,
Words can't describe how much I appreciate the kindness, support and concern that the two of you
expressed to me during our meeting today. Please know that I couldn't be more serious about
curtailing my "outside" activities and working with you to optimize the advantages such relationships have for Emory and minimizing any downside. I will prepare a list of my current activities and my thoughts as to how to reduce them to a more than acceptable level. As you would imagine, these activities are quite diverse and I will seek your guidance when I am uncertain in one or another area. I don't know if I can be a leader of change here, but I am certainly willing to help in any way. In the end, know that I will adhere to any standards the two of you see fit to impoBe. The most important issue here is the Department, the School of Medicine, EmoryHealthcare and
|
|
Bookmark:
|
http://dida.library.ucsf.edu/tid/oxx09v10
|
|
| |
8.
Re: Agreements
|
Document Date:
|
20031001
|
|
Author:
|
Nemeroff, Charles
|
|
Recipient:
|
Adkison, Claudia R
|
|
Document Type:
|
e-mail|memo
|
|
Named Person:
|
Brenda|Houpt
|
|
Named Organization:
|
Cypress|Merck|Otsuka|Acadia|American Foundation for Suicide Prevention|Wyeth-Ayerest|BMS|Janssen|GSK|Eli Lilly|Glaxo-Smith Kline|Squibb|AstraZeneca|Bristol-Myers
|
|
Case Number:
|
US Senate Finance Committee
|
|
Bates Number:
|
SENFIN0005-0006
|
|
Search Terms in Context:
|
I I
From: Sent: To: Cc:
Nemeroff, Charles B
Wednesday, October 01, 2003 11:04 PM
Adkison, Claudia R
Subject:
Re: agreements
Dear Claudia, I sent over the standing agreements I have with external groups today, e.g. Cypress, Merck, Otsuka, Acadia,etc. in terms of the other entitites you mentioned, I serve on the Board of Directors of the American Fdn for Suicide Prevention and we have two grants from them but I recieve no remuneration from them. I have not consulted with Wyeth for some time and when I did, there was no ongoing contract, just a fee per weekend meeting but there have been none in quite some time. I sent over my consulting agreement with BMS which is very modest and rare to say the least. As for Janssen, I have to dig up the agreement and send it to you, GSK no standing contract, I chair their ad board 2-3 times per year and I am paid per board meeting at a standard rate of $5K per weekend. I visit Lilly 2-3 times per year for 1 day and am remunerated at the rate of $3K. All pay for travel
|
|
Bookmark:
|
http://dida.library.ucsf.edu/tid/oxx09c10
|
|
| |
9.
[Letter from Charles Nemeroff inviting himself to submit an article for the special supplement edition of Depression and Anxiety]
|
Document Date:
|
20000209
|
|
Author:
|
Nemeroff, Charles
|
|
Corporate Author:
|
Emory University
|
|
Recipient:
|
Nemeroff, Charles
|
|
Corporate Recipient:
|
Emory University
|
|
Document Type:
|
letter
|
|
Named Person:
|
Ressler, Kerry
|
|
Case Number:
|
US Senate Finance Committee
|
|
Bates Number:
|
SENFIN0001-0002
|
|
Search Terms in Context:
|
DEPRESSION AND ANXIETY
Editors-In-Chief, CHARLES B. NEMEROFF, M.D., PH.D. and THOMAS W. UHDE, M.D.
DEPRESSION Editor-In-Chief
Ourles B. Nemeroff. MD. PhD
Rcunette W. Harris Professor and Chairman
Department of Psychiatry and
Behavioral Sciences Emory University School of Medicine 1639 Pierce Drive Suite 4000 Allant». GA 30322-4900
*T\
*orvw"W
February 9,2000
Associate Editor for Basic Science Jay M. Weiss. PhD Emory University School of Medicine
Associate Editor for Clinical Science
Alan F. Schauberg, MD Stanford Unversiry School of Medicine
Dear Me:
Book Review Editor
Renato Alarcon. MD
VA Medical Center, Allanta
In order to celebrate the 5* anniversary of the introduction of EfFexor, a supplement to Depression and Anxiety will be published. The purpose of this letter is to invite you to write an article for this special issue entitled "The Role of Serotonergic and Noradrenergic Systems in the Pathophysiology of Emory university school of Medici(gepress|on an(j Anxiety Disorders". This a
|
|
Bookmark:
|
http://dida.library.ucsf.edu/tid/oxx09a10
|
|
| |
10.
RE: Comments on corrigendum and the broader topic
|
Document Date:
|
20060720
|
|
Author:
|
Nemeroff, Charles
|
|
Corporate Author:
|
Emory University
|
|
Recipient:
|
Adkison, Claudia R
|
|
Corporate Recipient:
|
Emory University
|
|
Document Type:
|
e-mail|memo
|
|
Named Person:
|
Carroll|Rubin|Schatzberg, Alan|Bird, SJ|Fishbein, Estelle|Rhoades, LJ|Fotion, N|Conrad, CC|Carey, Benedict|Charney, Dennis|Rush, A. John|Carlat, Daniel|Sackeim, Harold
|
|
Named Organization:
|
Cyberonics|FDA|Mechanism of Action Advisory Board|Duke|Mt. Sinai|NIH|Stanford|University of Texas Southwestern Medical Center|Columbia
|
|
Case Number:
|
US Senate Finance Committee
|
|
Bates Number:
|
SENFIN0074-0090
|
|
Search Terms in Context:
|
Page 1 of 10
From: Charles B. Nemeroff [•¦¦i@emory.edu]
Sent: Thursday, July 20, 2006 9:18 PM
To: Adkison, Claudia R
Cc: Tomlawley
Subject: Re: Comments on corrigendum and the broader topic
Dear Claudia,
First and foremost again, please know that I am very grateful to you and Tom for your continued support. As I have said to you many times, I don't think we have very many differences of opinion in this arena. I would like to clarify several points that you raised that are actually not accurate and I think very important in the chain of events outlined below. I will really try to be brief. Cyberonics is a Houston based company that markets VNS for the treatment of Pharmacoresistent Epilepsy, This use is approved by the FDA. When it was noted that many epileptic patients exhibited mood improvement after VNS even if their seizure disorder was not improved, studies to test its efficacy in severe depression were initiated and ultimately it was approved for treatment of refractory depres
|
|
Person Copied:
|
Lawley, Tom
|
|
Bookmark:
|
http://dida.library.ucsf.edu/tid/oxx09t10
|
|
| |
|
Prev
Next
|
